Mutagenicity of hydroxyurea in lymphocytes from patients with sickle cell disease

Hydroxyurea is commonly used in the treatment of myeloproliferative diseases and in patients with sickle cell disease (SCD). The use of this antineoplastic agent in patients with SCD is justified because of the drug's ability to increase fetal hemoglobin levels, thereby decreasing the severity...

Full description

Bibliographic Details
Published in:Genetics and Molecular Biology
Main Authors: Khayat André Salim, Guimarães Adriana Costa, Cardoso Plínio Cerqueira, Lima Patrícia Danielle Lima de, Bahia Marcelo de Oliveira, Antunes Lusânia M. Greggi, Burbano Rommel Rodríguez
Format: Article
Language:English
Published: Sociedade Brasileira de Genética 2004-01-01
Subjects:
hydroxyurea
sickle cell disease
mutagenesis
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572004000100019

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572004000100019

Similar Items